UEMS-EACCME

Maintaining Patient QoL through Optimal Management of ADC-Associated AEs

Patients with HER2-negative metastatic breast cancer (MBC) who receive antibody-drug conjugates (ADCs) may experience a spectrum of adverse events (AEs) that can lower their quality of life (QoL). Patients and caregivers rely on their care team…

Clinical Trial Data with ADCs: New Options for HER2-Negative MBC

The rapidly shifting therapeutic landscape for HER2-negative metastatic breast cancer (MBC) challenges clinicians to stay up-to-date on emerging clinical trial data, as well as recommendations on therapy selection and sequencing. Unfamiliarity with antibody-drug conjugate (ADC) treatment…